Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2003

01.06.2003 | Original Article

Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms

verfasst von: Anna Christina Pfannenberg, Susanne Martina Eschmann, Marius Horger, Regina Lamberts, Reinhard Vonthein, Claus D. Claussen, Roland Bares

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

The aim of this prospective study was to evaluate anatomical-functional image fusion using the new technology of combined transmission and emission tomography (SPET/CT) in patients with neuroendocrine tumours (NET). Fifty-four patients with known or suspected NET prospectively underwent both tumour scintigraphy with 111In-octreotide (n=43) or 123I-MIBG (n=11) and contrast-enhanced high-end spiral CT. Scintigraphy was performed using a gamma camera (Millennium VG & Hawkeye, GE) with an integrated X-ray tube for combined transmission and emission tomography. SPET and high-end CT were interpreted blinded with regard to localisation and classification of lesions. Analysis of fused images (SPET/CT) was done on a lesion-by-lesion basis, followed by re-evaluation of SPET and high-end CT by consensus. The standard of reference for confirming the presence or absence of malignancy was either histopathology or clinical and imaging follow-up data. A total of 120 lesions were identified by CT and/or scintigraphy. This group included four patients with negative SPET but eight liver lesions on CT that were proven to be metastases. We excluded from the analysis two patients with no evidence of tumour on either modality, two lesions that lacked comparison with the standard of reference and two patients, each with two lesions, who were lost to follow-up. In 56 of the 114 evaluated lesions (49%), the results of SPET and CT were concordant; all lesions were interpreted as malignant. In 58 of 114 lesions (51%), consensus reading of fused images changed the image interpretation of 39 CT scans and 19 SPET studies: 31 lesions previously interpreted as equivocal (n=10) or benign (n=21) were re-classified as malignant and 27 lesions previously interpreted as equivocal (n=19) or malignant (n=8) were re-evaluated as benign. The highest accuracy (99%) in classifying NET lesions was achieved by combined analysis of SPET/CT ("hawkeye") and high-end CT. The specificity of SPET/CT was significantly higher than that of CT alone (P=0.0026) and slightly higher than that of SPET alone, but the accuracy of SPET/CT was inferior to that of side-by-side analysis of SPET and high-end CT (P=0.013) or visual correlation of SPET/CT and high-end CT (P<0.0001). Therapy was changed in 14 of 50 patients (28%) owing to the results of image fusion: in five patients tumour could be excluded, three patients were spared unnecessary surgery because of additional lesions indicating systemic tumour spread, in four patients the surgical approach was changed owing to precise tumour localisation and minimising of the surgical field, and in two patients medical and radiopeptide therapy was changed. Anatomical-functional image fusion allows for improved localisation and characterisation of NET with resultant alteration of the treatment approach in a substantial proportion of patients.
Literatur
1.
Zurück zum Zitat Öberg K. Neuroendocrine gastrintestinal tumors—a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10:53–58. Öberg K. Neuroendocrine gastrintestinal tumors—a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10:53–58.
2.
Zurück zum Zitat Shebani O, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999; 6:815–823. Shebani O, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999; 6:815–823.
3.
Zurück zum Zitat Kulke MH, Mayer J. Carcinoid tumors. N Engl J Med 1999; 340:858–868. Kulke MH, Mayer J. Carcinoid tumors. N Engl J Med 1999; 340:858–868.
4.
Zurück zum Zitat Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco H, Dodd GD. Carcinoid tumors: Imaging procedures and interventional radiology. World J Surg 1996; 20:147–156. Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco H, Dodd GD. Carcinoid tumors: Imaging procedures and interventional radiology. World J Surg 1996; 20:147–156.
5.
Zurück zum Zitat Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, Van Hagen M, Postema PTE, De Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, Van Hagen M, Postema PTE, De Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731.
6.
Zurück zum Zitat Krenning EP, Kwekkeboom DJ, Reubi JC. Peptide receptor scintigraphy in oncology. Peptide receptor scintigraphy in oncology. In: Murray IPC, Ell PJ,eds. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998:859–870. Krenning EP, Kwekkeboom DJ, Reubi JC. Peptide receptor scintigraphy in oncology. Peptide receptor scintigraphy in oncology. In: Murray IPC, Ell PJ,eds. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998:859–870.
7.
Zurück zum Zitat Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125:26–34. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125:26–34.
8.
Zurück zum Zitat Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word. Gastroenterology 1997; 112:583–590. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word. Gastroenterology 1997; 112:583–590.
9.
Zurück zum Zitat Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumours. Digestion 2000; 62 (Suppl 1):39–44. Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumours. Digestion 2000; 62 (Suppl 1):39–44.
10.
Zurück zum Zitat Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, Le Guludec D. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853–858. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, Le Guludec D. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853–858.
11.
Zurück zum Zitat Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland BJ, Monetti N, Bombardieri E. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25:1396–1403. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland BJ, Monetti N, Bombardieri E. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25:1396–1403.
12.
Zurück zum Zitat Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. "Anatometabolic" tumor imaging: fusion of FDG-PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993; 34:1190–1197. Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. "Anatometabolic" tumor imaging: fusion of FDG-PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993; 34:1190–1197.
13.
Zurück zum Zitat Shreve PD. Adding structure to function (invited commentary). J Nucl Med 2000; 41:1380–1382. Shreve PD. Adding structure to function (invited commentary). J Nucl Med 2000; 41:1380–1382.
14.
Zurück zum Zitat Patton JA, Debelke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with x-ray tube-based attenuation maps. J Nucl Med 2000; 41:1364–1368. Patton JA, Debelke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with x-ray tube-based attenuation maps. J Nucl Med 2000; 41:1364–1368.
15.
Zurück zum Zitat Even-Sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D, Guralnik L, Werbin N, Iosilevsky G, Israel O. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 2001; 42:998–1004. Even-Sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D, Guralnik L, Werbin N, Iosilevsky G, Israel O. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 2001; 42:998–1004.
16.
Zurück zum Zitat Eubank WB, Mankoff DA, Schmiedl UP, Winter TC, Fisher ER, Olshen AB, Graham MM, Eary JF. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. AJR 1998; 171:1103–1110. Eubank WB, Mankoff DA, Schmiedl UP, Winter TC, Fisher ER, Olshen AB, Graham MM, Eary JF. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. AJR 1998; 171:1103–1110.
Metadaten
Titel
Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms
verfasst von
Anna Christina Pfannenberg
Susanne Martina Eschmann
Marius Horger
Regina Lamberts
Reinhard Vonthein
Claus D. Claussen
Roland Bares
Publikationsdatum
01.06.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1160-y

Weitere Artikel der Ausgabe 6/2003

European Journal of Nuclear Medicine and Molecular Imaging 6/2003 Zur Ausgabe